United States: Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation - Goodwin Procter LLP

Mondaq

11 Jan 2024 0 shares 1 views

United States: Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation - Goodwin Procter LLP

Mondaq

Published 11 Jan 2024

As we have previously reported, in November 2023 Regeneron Pharmaceuticals, Inc. ("Regeneron") filed complaints against Celltrion, Samsung Bioepis and Formycon...

Full Article

United States: Updates On Aflibercept BPCIA Litigation - Goodwin Procter LLP

The proposed schedule also provides dates for document discovery and depositions.

Mondaq 10 Jan 2024

United States: Breaking: Judgment In Regeneron v. Mylan (Aflibercept) BPCIA Case Finding Some Claims Of Asserted Patents Valid And Infringed - Goodwin Procter LLP

As previously reported by Big Molecule Watch, trial in Regeneron's BPCIA case against Biocon regarding Biocon's proposed..

Mondaq 08 Jan 2024

United States: Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation - Goodwin Procter LLP

United States: Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation - Goodwin Procter LLP

You might like

Related news coverage

United States: Updates On Aflibercept BPCIA Litigation - Goodwin Procter LLP

United States: Breaking: Judgment In Regeneron v. Mylan (Aflibercept) BPCIA Case Finding Some Claims Of Asserted Patents Valid And Infringed - Goodwin Procter LLP

Advertisement